Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience

[1]  M. Hoenigl,et al.  Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement , 2020, Journal of fungi.

[2]  M. Konopleva,et al.  Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  G. Papanicolaou,et al.  Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm. , 2020, Medical mycology.

[4]  Yeon Joo Lee,et al.  A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT). , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  B. Noble,et al.  Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic-cell transplant recipients. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Badali,et al.  Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.

[7]  G. Rahav,et al.  Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system , 2019, Medical mycology.

[8]  D. Kontoyiannis,et al.  Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology , 2019, Mycoses.

[9]  M. Hakki,et al.  Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre , 2019, Mycoses.

[10]  V. Athans,et al.  Real‐world use—Isavuconazole at a large academic medical center , 2019, Mycoses (Berlin).

[11]  D. Kontoyiannis,et al.  Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients , 2018, Mycoses.

[12]  D. Kontoyiannis,et al.  Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  C. Beigelman-Aubry,et al.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  P. Kowey,et al.  QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization , 2017, Clinical pharmacology and therapeutics.

[15]  D. Denning,et al.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  J. Perfect,et al.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.

[17]  J. Baddley,et al.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.

[18]  Marisa H Miceli,et al.  Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D. Kontoyiannis,et al.  How I treat mucormycosis. , 2011, Blood.

[20]  G. Papanicolaou,et al.  Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.